Bass and Spangenberg target another pharma company through IPR
02 April 2015
|
Michael Loney, New York
UPDATED APRIL 7 TO INCLUDE NEW IPR: Hayman Capital’s Kyle Bass and IP Nav’s Erich Spangenberg have targeted a second and third pharmaceutical company at the PTAB, filing inter partes review petitions challenging patents owned by Shire and Jazz
It may have been April 1, but hedge fund manager Kyle Bass was not fooling when he continued to make good on his promise to try to invalidate big pharmaceutical’s companies’ patents through the Patent Trial and Appeal Board (PTAB)....
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here